February 7th 2025
This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.
FDA Issues a CRL for Venatorx Pharmaceuticals’ Antibiotic for Treatment of Complicated UTI
February 23rd 2024The federal agency did not request further trials for the investigational therapy, cefepime-taniborbactam, but wanted more information about its chemistry, manufacturing, and controls.
Read More
Investigational Antibiotic Outperforms Meropenem in Treating Complicated UTI
February 16th 2024A recently published study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.
Read More
Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?
November 28th 2023The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Read More
Antibiotic De-Escalation: Is This the Right Outcome Measure?
November 16th 2023The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
Read More
Two Pragmatic Approaches to Skin and Soft Tissue Infections
November 14th 2023Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.
Read More
Changing the Antibiotic Reimbursement Model to Encourage Drug Development Proliferation
November 12th 2023Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.
Watch